BETA Technologies launches IPO of 25 million shares priced $27-$33
Investing.com -- Onward reported a significant acceleration in ARC-EX system sales during the third quarter, with 40 units sold compared to 20 in Q2 and 10 in Q1, bringing total placements to 70 across more than 50 US sites.
The company’s quarterly revenue exceeded €1 million for the first time, reflecting both higher sales volumes and sustained pricing. Shares rose 15% in Monday’s trading following the announcement.
This performance validates Onward’s second-half ramp-up guidance and aligns with revised full-year forecasts of 140-150 units.
The commercial rollout is progressing as expected, supported by positive user feedback and continued expansion of the company’s clinical footprint. The sales trajectory confirms growing demand and execution of the company’s focused go-to-market strategy.
Onward recently received CE Mark approval for ARC-EX, allowing both clinic and home use in Europe. While European sales growth will depend on reimbursement timing, this regulatory milestone adds long-term strategic options for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.